FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:2464-2466 June 12, 2003 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Graham, D. Y. Related Article by Chan, F. K.L. PubMed Citation

To the Editor: In their report on the use of celecoxib as compared with diclofenac plus omeprazole to reduce the risk of recurrent ulcer bleeding in patients with arthritis, Chan et al. (Dec. 26 issue)¹ state that the probability of recurrent bleeding was 4.9 percent in the celecoxib-treated patients (7 of 144) and 6.4 percent in those receiving the combination of diclofenac and omeprazole (9 of 143). These bleeding complications were considered by the adjudication committee to meet the criteria for recurrent ulcer bleeding, which was the primary end point. However, for the purposes of clinical practice, the eight other . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.